Mitsubishi Chemical Group Corp Digital Transformation Strategy Analysis Report 2023: Accelerators, Incubators, and Other Innovation Programs

2024-02-02
DUBLIN, Feb. 2, 2024 /PRNewswire/ -- The "Mitsubishi Chemical Group Corporation - Digital Transformation Strategies" company profile has been added to
ResearchAndMarkets.com's offering.
This report provides insight into Mitsubishi Chemical's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts.
Mitsubishi Chemical Group Corp (MCGC), formerly Mitsubishi Chemical Holdings Corp is a diversified chemical company. Its products and services include advanced polymers, high-performance chemicals, high-performance films, advanced moldings and composites, petrochemicals, carbon, industrial gases, methyl methacrylate, and environment and living solutions.
MCGC also provides ethical pharmaceuticals, diagnostic reagents and instruments, capsules and pharmaceutical equipment, active pharmaceutical ingredients and intermediates, and self-health check services. The company serves several sectors, including mobility, environment and new energy, information technology, electronics and display, medical, food and bio products, packaging, labels and films and healthcare.
In June 2022, MCHG and Plug and Play Japan launched the TANAMIN Digital Health Challenge. This challenge will accept submissions from digital health startups proposing cutting-edge technology solutions to improve well-being of ALS patients and their families, digitalize Decentralized Clinical Trial, or increase preventative vaccinations in Japan. Finalists of the challenge will be offered an opportunity to pursue a paid proof of concept with MCHG, opening a potential long-term partnership with Mitsubishi Tanabe Pharma.
Launched in December 2022, Growth Garage Business Incubator of Advanced Materials Division of Mitsubishi Chemical Group is inviting entrepreneurs, innovators and founders focused on lightweight parts and applications with carbon fiber-reinforced plastics (CFRP), to submit their idea to the composite Engineering Challenge. The winners of challenge will gain access to technology resources and support in material selection, tool design, scalability, and design for manufacturing. Additionally, the winners will also receive a support package of $25,000, access to industry experts, Mitsubishi's corporate venture capital arm and network to create global exposure.
Scope
Mitsubishi is installing and applying digital technologies to improve business efficiency and positioned digitalization as a strategic priority in its business model to enhance customer experience and enable business transformation. The company is modernizing its approaches to maximize benefits of cloud computing, mobile devices, and next-generation network technology to tap new opportunities and enhance cost efficiencies.
Mitsubishi is promoting digital technologies to realize precision medicine. For instance, it is collaborating with academia and AI venture companies to develop AI technology for drug screening, which enables accelerated drug evaluation using large-scale image data. The company also aims to apply this technology to drug screening based on genetic polymorphism and drug screening using human induced pluripotent stem (IPS) cells from patients.
Mitsubishi joined the IBM Quantum Network to collaborate with IBM scientists to model and analyze the deep molecular structures of potential OLED materials on IBM Quantum devices. The research teams of Mitsubishi Chemical, Keio University, and IBM Quantum are working to better understand lithium-oxygen's potential as an energy source by using new algorithms that take advantage of quantum computing to develop lithium-oxygen batteries.
Reasons to Buy
Gain insights into Mitsubishi's tech operations.
Gain insights into its tech strategies and innovation initiatives.
Gain insights into its technology themes under focus.
Gain insights into various product launches, partnership, investments and acquisition strategies.
Key Topics Covered:
Overview
Digital Transformation Strategy
Accelerators, Incubators, and Other Innovation Programs
Technology Focus
Technology Initiatives
Investment
Acquisitions
Partnership, Investment & Acquisition Network Map
ICT Budget and Contracts
Key Executives
Contact the Publisher
A selection of companies mentioned in this report includes
Allganize
Kebotix
Circularise
AM Polymers
Atum3D
EditForce
Solvay
Dymon
Celanese
ENEOS
Mura Technology
KBR
For more information about this company profile visit https://www.researchandmarkets.com/r/n74bn4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。